HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SL 59.1227

structure in first source

Also Known As:

3-((cyclopropylcarbonyl)amino)-N-(2-(dimethylamino)ethyl)-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)benzamide

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Briand, V: 1 article (11/2000)
2.	Cremer, G: 1 article (11/2000)
3.	Duval, N: 1 article (11/2000)
4.	Favennec, E: 1 article (11/2000)
5.	Grosset, A: 1 article (11/2000)
6.	Hoornaert, C: 1 article (11/2000)
7.	Janiak, P: 1 article (11/2000)
8.	Latham, C: 1 article (11/2000)
9.	Lorrain, J: 1 article (11/2000)
10.	O'Connor, S E: 1 article (11/2000)

Related Diseases

1.	Ventricular Tachycardia 11/01/2000 - "3. In anaesthetized rats following left coronary artery occlusion (7 min) and reperfusion (10 min) SL 59.1227 (10 - 100 microg kg(-1) min(-1) i.v.) inhibited ischaemia-mediated ventricular tachycardia (71 - 100%) and reperfusion-induced ventricular fibrillation (75 - 87%) and prevented mortality. "
2.	Ventricular Fibrillation 11/01/2000 - "3. In anaesthetized rats following left coronary artery occlusion (7 min) and reperfusion (10 min) SL 59.1227 (10 - 100 microg kg(-1) min(-1) i.v.) inhibited ischaemia-mediated ventricular tachycardia (71 - 100%) and reperfusion-induced ventricular fibrillation (75 - 87%) and prevented mortality. "
3.	Infarction (Infarctions) 11/01/2000 - "Infarct size measured as a percentage of the area at risk was 36.2+/-3.4% (control group) versus 15.3+/-3.9% (SL 59.1227 0.6 mg kg(-1) i.v.). "